The dynamics of Relapsed/Refractory (R/R) Multiple Myeloma (MM) market are anticipated to change owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies such as bb2121/bb21217 (Celgene), Melflufen (Oncopeptides), JNJ-68284528 (Janssen Research & Development), P-BCMA-101 CAR-T cells (Poseida Therapeutics), Anti-BCMA CAR-T (CARsgen), and others in the upcoming years.
“Relapsing Refractory Multiple Myeloma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Relapsing Refractory Multiple Myeloma Market.
The Relapsing Refractory Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Relapsing Refractory Multiple Myeloma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Relapsing Refractory Multiple Myeloma and the aggregate therapies developed by major pharma companies.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Relapsing Refractory Multiple Myeloma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Relapsing Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Products have been categorized under various Molecule types, such as
Learn How the Ongoing Clinical & Commercial Activities will Affect the Relapsing Refractory Multiple Myeloma Therapeutic Segment @
The Leading Companies in the Relapsing Refractory Multiple Myeloma Therapeutics Market Include:
Allogene Therapeutics, Anaveon AG, Arcellx, Array Biopharma, Bristol-Myers Squibb, Cartesian Therapeutics, Cellectis, Gilead Sciences, Harpoon Therapeutics, Heidelberg Pharma AG, Hrain Biotechnology Co., Ltd., I-MAB Biopharma, Ichnos Sciences, iTeos Therapeutics, Luminary Therapeutics, Novartis, ONK Therapeutics, Oricell Therapeutics, Pfizer, Poseida Therapeutics, Regeneron Pharmaceuticals, Seagen Inc., Sorrento Therapeutics, Takeda, TeneoOne, Trillium Therapeutics Inc., Virtuoso BINco, Inc., Xencor, and others.
Relapsing Refractory Multiple Myeloma Emerging and Marketed Drugs Covered in the Report Include:
Mezigdomide: Bristol-Myers Squibb
Iopofosine: Cellectar Biosciences, Inc.
ORIC-533: ORIC Pharmaceuticals
JNJ-68284528: Legend Biotech Biotech/Janssen Biotech
Xpovio: Karyopharm Therapeutics
JNJ-68284528: Janssen Research & Development
P-BCMA-101 CAR-T cells: Poseida Therapeutics
Anti-BCMA CAR-T: CARsgen
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
Latest Key Update in the Relapsing Refractory Multiple Myeloma Therapeutics Market
On April 04, 2023, Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to CB-011, which is being developed for relapsed or refractory multiple myeloma (r/r MM). CB-011 is being evaluated in the company’s ongoing CaMMouflage Phase 1 clinical trial in patients with r/r MM.
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Relapsing Refractory Multiple Myeloma Current Treatment Patterns
4. Relapsing Refractory Multiple Myeloma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Relapsing Refractory Multiple Myeloma Late Stage Products (Phase-III)
7. Relapsing Refractory Multiple Myeloma Mid-Stage Products (Phase-II)
8. Relapsing Refractory Multiple Myeloma Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Relapsing Refractory Multiple Myeloma Discontinued Products
13. Relapsing Refractory Multiple Myeloma Product Profiles
14. Key Companies in the Relapsing Refractory Multiple Myeloma Market
15. Key Products in the Relapsing Refractory Multiple Myeloma Therapeutics Segment
16. Dormant and Discontinued Products
17. Relapsing Refractory Multiple Myeloma Unmet Needs
18. Relapsing Refractory Multiple Myeloma Future Perspectives
19. Relapsing Refractory Multiple Myeloma Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States